CCDR – Therapeutic Virus Production Platform

Designação do Projeto | Project Name | Plataforma de Produção de Vírus Terapêuticos | Therapeutic Virus Production Platform

Código do Projeto | Project Code | LISBOA2030 – Programa Regional de Lisboa 2021-2027

Entidade Coordenadora | Coordinating Entity | iBET – Instituto de Biologia Experimenta e Tecnológica

Agência de Financiamento| Funding Agency | FEDER – Fundo Europeu de Desenvolvimento Regional

Data de Início | Starting Date | 01/09/2024

Data de Conclusão | Conclusion Date | 31/12/2026

Custo Total Eligível | Total Eligible Cost | €1.823.321,00

Breve Descrição do Projeto | Brief Project Description | Therapeutic Virus Production Platform

The Therapeutic Virus Production Platform is a strategic investment initiative designed to significantly enhance iBET’s infrastructure, facilities, and equipment. Through targeted interventions, the plan aims to create modern, fit-for-purpose spaces capable of addressing emerging challenges, particularly in the fields of biopharmaceuticals and vaccines. These upgraded spaces will be equipped with the necessary tools to support the achievement of the platform’s defined objectives.

Over the past 25 years, iBET has developed bioprocesses and characterization tools for adenoviruses, lentiviruses, adeno-associated viruses, and vaccine viruses – covering approximately 90% of the viral vectors currently used in gene therapy. More recently, with the growing prominence of cell therapies, iBET has successfully tackled the challenges of cell transduction for immunotherapy (e.g., CAR-T), leveraging its expertise and infrastructure in lentiviral systems.

In this context, the proposed investment in the Platform is expected to reinforce existing partnerships and foster new collaborations with industrial key players in the biopharmaceutical sector, particularly in gene and cell therapy, including next-generation vaccines.

This initiative will contribute to positioning Portugal as a recognized hub for pharmaceutical and biotechnology innovation, enhancing the country’s potential for exporting advanced therapy medicinal products (ATMPs).

Financiado por | Funded by: